Company intelligence / Profile preview

PRG Science & Technology

Geumjeong-gu, Busan, Koreaprgst.com ↗

Ownership: Private
Development stage: Phase 2

Overview

PRG Science & Technology is advancing several small molecule therapeutics targeting rare genetic diseases. Its most advanced candidates are in Phase 2 clinical trials for progeroid syndromes such as HGPS and WS. The ALS candidate Amisodin is entering Phase 1 trials. The company leverages a proprietary PPI inhibitor platform to identify novel drug candidates with potential expansion into broader aging-related indications if safety is established in ongoing studies[4][6].

Therapeutic areas: Rare DiseasesNeurology
Modalities: Small molecules[1][7]Chemical drugs[1][7]
Industry: Biotech

Drug pipeline

2 assets

Progerinin

1 more asset in the full pipeline.

Request access →

Partnerships

No major pharmaceutical partnerships publicly disclosed as of current data.

Beyond the preview

Go deeper on PRG Science & Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRG Science & Technology.

Explore the full profile